Condition: Bladder Cancer · Sponsor: Early is Good Inc.
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
This description comes directly from the study's public registry record.
Thakshila Liyanage, PhD · (317) 941-6953 · thakshila@earlyisgood.com
Always discuss trial participation with your own doctor first.
| Arkansas Urology Research Center | Little Rock, Arkansas, United States | Recruiting |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05982561